Moleculin Biotech
MBRX
15 hedge funds and large institutions have $1.53M invested in Moleculin Biotech in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.
0.42% more ownership
Funds ownership: 0.05% → 0.46% (+0.42%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
25% less funds holding
Funds holding: 20 → 15 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
66% less capital invested
Capital invested by funds: $4.44M → $1.53M (-$2.92M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.1K |
| 2 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$5.76K |
| 3 |
FIM
FWL Investment Management
Dallas,
Texas
|
+$2.35K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.28K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$557K |
| 2 |
Renaissance Technologies
New York
|
-$111K |
| 3 |
State Street
Boston,
Massachusetts
|
-$61.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$55.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$46K |
MBRX Hedge Fund Activity: Q1 2024 in Review
15 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2024, worth a combined $1.53M — down 66% from $4.44M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MBRX and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $28.1K. The largest seller was Armistice Capital, cutting an estimated $557K.
- 15 institutional investors held Moleculin Biotech (MBRX) as of Q1 2024, down from 20 in Q4 2023.
- Funds reported $1.53M of Moleculin Biotech stock for Q1 2024, down 66% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q1 2024 and 8 closed out, a net change of -5 holders.
- The largest Moleculin Biotech buyer in Q1 2024 was Vanguard Group, an estimated $28.1K added.
- The largest Moleculin Biotech seller in Q1 2024 was Armistice Capital, an estimated $557K sold.
Based on aggregated 13F filings for Q1 2024.